BC Innovations | May 2, 2019
Product Development

Evelo breaks from the microbiome pack with non-colonizing bugs

While most companies developing bugs as drugs want their microbes to flourish in hosts, Evelo is designing microbial candidates that exert therapeutic effects without colonizing, replicating or metabolizing -- acting more like biologics than live...
BC Extra | Mar 11, 2019
Company News

Seres, AZ partner on microbiome research to treat cancer, predict response

Seres gained $1.27 (25%) to $6.38 on Monday after it announced a three-year partnership with AstraZeneca to evaluate microbiome-based approaches to improve and predict patient response to immunotherapies. Seres Therapeutics Inc. (NASDAQ:MCRB) will receive $20...
BC Week In Review | May 11, 2018
Financial News

Evelo raises $85M in IPO

Microbiome company Evelo Biosciences Inc. (NASDAQ:EVLO) raised on May 8 $85 million through the sale of 5.3 million shares at $16 in an IPO underwritten by Morgan Stanley, Cowen, BMO Capital Markets and JMP Securities....
BC Extra | May 9, 2018
Financial News

Evelo raises $85M in IPO

Microbiome company Evelo Biosciences Inc. (NASDAQ:EVLO) raised $85 million through the sale of 5.3 million shares at $16 in an IPO underwritten by Morgan Stanley, Cowen, BMO Capital Markets and JMP Securities. Evelo added $0.25...
Proposed Offerings | Apr 20, 2018
Proposed Offerings

Microbiome company Evelo proposes $100M IPO

Microbiome company Evelo Biosciences Inc. (Cambridge, Mass.) proposed on April 13 to raise $100 million in an IPO on NASDAQ underwritten by Morgan Stanley, Cowen, BMO Capital Markets and JMP Securities. Evelo has a portfolio...
BC Extra | Apr 13, 2018
Financial News

Evelo proposes $100M IPO

Microbiome company Evelo Biosciences Inc. (Cambridge, Mass.) proposed to raise $100 million in an IPO on NASDAQ underwritten by Morgan Stanley, Cowen, BMO Capital Markets and JMP Securities. Evelo has a portfolio of preclinical monoclonal...
Items per page:
1 - 6 of 6